Payment overview · 2025
General Payments
$334.09
17 reported records · 11 companies
Healthcare provider profile · identity verified
Antonios Papadopoulos, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MATTOON, IL · NPI 1467562116
Verified facts
What the public records show
CMS Open Payments records show Antonios Papadopoulos, MD received $334.09 in general payments during 2025 across 17 reported records.
UCB, Inc. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $71.85 | 21.5% | 3 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $62.16 | 18.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.34 | 15.1% | 3 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $24.50 | 7.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.39 | 7.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.66 | 6.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.27 | 5.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.05 | 5.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.39 | 4.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $14.59 | 4.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.89 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $334.09 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $71.85 | 3 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $62.16 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $24.50 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 668 | 196 |
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 120 |
| Furosemide | Furosemide | 323 | 98 |
| Losartan Potassium | Losartan Potassium | 306 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 80 |
| Alendronate Sodium | Alendronate Sodium | 254 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 69 |
| Gabapentin | Gabapentin | 176 | 51 |
| Omeprazole | Omeprazole | 161 | 45 |
| Carvedilol | Carvedilol | 160 | 42 |
| Allopurinol | Allopurinol | 158 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 119 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 30 |
| Potassium Chloride | Potassium Chloride | 106 | 41 |
| Metformin Hcl | Metformin Hcl | 101 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 30 |
| Simvastatin | Simvastatin | 86 | 27 |
| Calcitriol | Calcitriol | 82 | 20 |
| Chlorthalidone | Chlorthalidone | 82 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 17 |
| Montelukast Sodium | Montelukast Sodium | 76 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 14 |
| Lorazepam | Lorazepam | 69 | 16 |
| Ezetimibe | Ezetimibe | 67 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 20 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 61 | 22 |
| Eliquis | Apixaban | 61 | 19 |
| Metformin Hcl Er | Metformin Hcl | 60 | 24 |
| Trazodone Hcl | Trazodone Hcl | 59 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 16 |
| Sertraline Hcl | Sertraline Hcl | 53 | 17 |
| Spironolactone | Spironolactone | 53 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 15 |
| Famotidine | Famotidine | 49 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 15 |
| Alprazolam | Alprazolam | 45 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 11 |
| Jardiance | Empagliflozin | 43 | 11 |
| Pregabalin | Pregabalin | 42 | 16 |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Torsemide | Torsemide | 41 | 15 |
| Tramadol Hcl | Tramadol Hcl | 38 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 27 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 11 |
| Veltassa | Patiromer Calcium Sorbitex | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 33 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 12 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 11 |
| Prednisone | Prednisone | 26 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 19 |
| Glipizide | Glipizide | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Topiramate | Topiramate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $334.09 · 17 records | UCB, Inc. | Bimzelx, Dexcom G6 Transmitter, EVENITY, GVOKE HYPOPEN, ISTURISA, Kerendia, LEQVIO, Omnipod, RECORLEV, Wegovy, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error